Purpose: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival
versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell …

Purpose Prostatic acid phosphatase (PAP) is a prostate tumor antigen. We have previously
demonstrated that a DNA vaccine encoding PAP can elicit antigen-specific CD8+ T cells in …

CTL-associated antigen 4 (CTLA4) is a costimulatory molecule expressed on activated T cells
that delivers an inhibitory signal to these T cells. CTLA4 blockade with antibody treatment …

B cells have been long studied for their role and function in the humoral immune system.
Apart from generating antibodies and an antibody-mediated memory response against …

Purpose: Preclinical data established IL15 as a homeostatic factor and powerful stimulator
of NK and CD8 + T-cell function, the basis for clinical testing. Experimental Design: A first-in-…

Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein
1 (PD-1) found on T and pro-B cells. Pembrolizumab prevents PD-1 ligation by both PD-…

Prior to the advent of VEGF-targeted therapies, renal cell carcinoma (RCC) was among the
few solid tumors shown to respond to cytokine-based therapies such as interleukin-2 (IL-2) …

At present, a variety of agents targeting tumor angiogenesis are under clinical investigation
as new therapies for patients with cancer. Overexpression of the α v β 3 integrin on tumor …

Immunomodulatory strategies, such as antibody therapy and cancer vaccines, are increasingly
being considered as potential adjuvant therapies in patients with advanced stage breast …

Prostate cancer is the most common newly diagnosed malignancy in men, and the second
most common cause of cancer-related death in the United States. The primary treatment for …